showed a trendp = 0.04
Long-term mortality showed a trend to superiority of CABG (10.6% versus 9.4%, p = 0.04), with trials showing moderate heterogeneity (I 2 = 25%).
Long-term mortality showed a trend to superiority of CABG (10.6% versus 9.4%, p = 0.04), with trials showing moderate heterogeneity (I 2 = 25%).